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Abstract
OBJECTIVE: To evaluate the efficacy and safety of
treatment based on syndrome differentiation of Tra-
ditional Chinese Medicine (TCM) for community-ac-
quired pneumonia (CAP).
METHODS: A total of 240 CAP patients were ran-
domly divided into the following two groups: the
control group was treated by anti-infection plus
conventional medicine treatment; and the trial
group was treated by TCM plus the above-men-
tioned treatment given to the controls. The course
of treatment was 14 days, and the patients were fol-
lowed up for 7 days.
RESULTS: Of the 240 patients, 235 accomplished
the whole process of treatment. The five patients
who withdrew from the study were brought into
an intent-to-treat analysis. The therapeutic effects
of the trial group were superior to those of the con-
trol group (P<0.01). The trial group took less time to
become clinically stable, with a higher score in the
quality of life (P<0.01). There were no significant dif-
ferences in mortality rate (P>0.05), white blood cell
count (P>0.05), bacterial clearance rate (P>0.05),
and adverse reactions between the two integrated
groups.
CONCLUSION: Treatment based on TCM syndrome
differentiation for CAP has the advantages of result-
ing in less time to achieve a stable clinical condi-
tion, improvement of clinical symptoms and quali-
ty of life, and is comparatively safe.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Community-acquired pneumonia (CAP) is a common
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infectious disease,1,2 which seriously threatens people's
life and QOL, especially for elderly patients.3 CAP has
an incidence of 3-40 per 1,000 inhabitants per year (in-
creasing with age), with a hospitalization rate of
40%-60%. The rate of CAP patients admitted to the
intensive care unit (ICU) is approximately 10% . The
mortality rate of hospitalized CAP patients is 10% .2
Western Medicine treatment for CAP includes anti-in-
fective4 and glucocorticoid therapy,5 which are useful
for bacterial clearance, improvement of clinical symp-
toms and signs, and pulmonary pathological changes.
However, with the appearance of transition of patho-
genic microorganisms and drug resistance, the inci-
dence and mortality rates of CAP are still not de-
creased.6,7 Traditional Chinese Medicine (TCM) treat-
ment for CAP has the advantages of improving clinical
symptoms, shortening the course of disease, preventing
the condition of the illness from worsening, and reduc-
ing the mortality rate, but these improvements need to
be confirmed by high-level evidence.8,9
Therefore, in the present study, a randomized con-
trolled multicenter clinical trial was designed to evalu-
ate the efficacy and safety of integrated treatment for
CAP based on TCM syndrome differentiation to pro-
vide objective evidence for clinical practice.
METHODS
Subjects
The patients recruited were those who had a diagnosis
of CAP and were hospitalized in four hospitals in the
period from January 2009 to January 2010 (The First
Affiliated Hospital of Henan College of Traditional
Chinese Medicine, Jiangsu Province Hospital of TCM,
The Affiliated Hospital of Shandong university of
TCM, and Qingdao Hospital of TCM).
Diagnostic criteria
The diagnostic criteria of Western Medicine were
made in accordance with the Diagnosis and Treatment
Guidelines for CAP stipulated by the Chinese Society
of Respiratory Diseases in 2006.10 The diagnostic crite-
ria of TCM were made by referring to our previous re-
search11.
Inclusion criteria
The inclusion requirements were as follows: 1) the pa-
tients met the diagnosis of CAP; 2) the patients met
the patterns of the syndrome of external wind-heat at-
tacking the lung, the syndrome of external cold and in-
ternal heat, the syndrome of phlegm-heat obstructed in
the lung, the syndrome of accumulation of
phlegm-dampness in the lung, the syndrome of defi-
ciency of pulmonosplenic Qi, and the syndrome of de-
ficiency of Qi and Yin; 3) aged 45-80 years; 4) no expe-
rience in other clinical intervention research 1 month
prior to recruitment; and 5) the patients received the
treatment voluntarily and gave informed consent.
Exclusion criteria
The following individuals were excluded: 1) pregnant
patients; 2) patients with confusion, dementia or any
type of mental illness; 3) patients with bronchiectasis,
active tuberculosis or lung abscess, a pathogenic micro-
organism that is an atypical pathogen, a fungus, or a vi-
rus; 4) patients with serious diseases, such as tumors,
heart failure, liver and kidney diseases, or hematopoiet-
ic system diseases; 5) patients with congenital or ac-
quired immune deficiency; 6) patients participating in
other clinical intervention research; and 7) patients
who were allergic to treatment drugs.
Withdrawal criteria
Patients were withdrawn for the following reasons: if
they had poor compliance that affected the evaluation
of efficacy and safety; those who violated the protocol;
those who dropped out of the study by themselves;
those who were lost in the follow-up period; and those
who were unfit to continue the trial because of serious
adverse reactions, complications, and special physiolog-
ical changes.
Rejection criteria
Patients were rejected if they were misdiagnosed or er-
roneously included, as well as those who did not take
the drugs or were not observed for at least one time
point.
Sample size
According to the relevant computing method of sam-
ple size, of the total of 240 patients, 120 were random-
ly assigned to the control group and 120 were assigned
to the trial group.
Randomization and blinding
The block randomization design was adopted and the
code number was distributed in a 1-to-1 ratio into the
trial group and control group. The random number
was generated by SAS 6.12 software (SAS Institute
Inc., Cary, NC, USA). The treatment regimen was de-
termined by the inclusion sequence of the patients and
the serial number for the drugs. No blinding method
was adopted in the trial.
Ethics approval and trial registration
The present study was approved by the Ethic Commit-
tee of The First Affiliated Hospital of Henan College
of TCM and was performed in accordance with the
ethical standards laid down in the Declaration of Hel-
sinki. All persons signed their informed consent prior
to their inclusion in the study. The batch number was
YFYKTLL2006-02.
Interventions
The patients in the control group were treated by an-
ti-infection plus conventional medicine treatment. The
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patients in the trial group were treated by TCM plus
the above-mentioned treatment given to the controls.
The conventional medicine treatment included the fol-
lowing. 1) General treatment: bed rest, keeping room
air circulated, isolation and disinfection, preventing
mixed infection, maintaining water and electrolyte bal-
ance, oxygen therapy, keeping the respiratory tract un-
blocked and promptly removing respiratory secretions,
and changing body position to benefit sputum dis-
charge. 2) Treatment according to clinical symptoms:
for fever (T ≥38.5°C), lowering the body temperature
first (using antipyretic analgesics, such as paracetamol);
and for severe cough, improving rest of the patients
with oral bromhexine hydrochloride (8 mg, three times
a day), using oral ambroxol hydrochloride tablets in
the presence of sticky sputum (30 mg, three times a
day), and in cases of gasping, aminophylline should be
added (0.1 g, three times a day). The antibiotic therapy
for community-acquired pneumonia should always be
adopted according to the Diagnosis and Treatment
Guideline for CAP stipulated by the Respiratory Dis-
ease Branch of the Chinese Medical Association in
2006.10 The TCM treatment was given according to
our previous research:12 1) Yinqiao San was used for the
syndrome of external wind-heat attacking the lung; 2)
Maxingshigan Tang and Qingjinhuatan Tang were
used for the syndrome of external cold and internal
heat; 3) Beimugualou San and Qingjinjianghuo Tang
were used for the syndrome of phlegm-heat obstructed
in the lung; 4) Banxiahoupu Tang and Sanziyangqin
Tang were used for the syndrome of accumulation of
phlegm-dampness in the lung; 5) Shenlingbaizhu San
was used for the syndrome of Qi deficiency of the lung
and spleen; 6) Shengmai San and Shashenmaidong
Tang were used for the syndrome of deficiency of both
Qi and Yin; 7) Qingying Tang and Xijiaodihuang Tang
were used for the syndrome of internal heat trapped in
the pericardium; and 8) for the syndrome of an in-
crease in pathogen and decrease in vital Qi, Shengmai
San was given to those with Yin exhaustion, and Sini
plus Renshen Tang were given to those with yang ex-
haustion.
The TCM treatment was given for 14 days, and pa-
tients were followed up for 7 days.
Observation and determination of outcome
Comprehensive therapeutic effects: According to the
evaluation standards of therapeutic effects described in
The Guidelines for Clinical Researching of Antimicro-
bial Drugs,12 "clinical cure" means that after treatment,
symptoms and physical signs disappear, and all the lab-
oratory values and pathogen examination results return
to normal. "Marked improvement" means that the con-
dition of the illness is obviously improved, but not all
results from examinations return to normal. "Improve-
ment" means that the condition of the illness is some-
what improved. "Failure" is defined as no improve-
ment or even aggravation.
Mortality: The total death rate of any cause during
treatment and in the follow-up period was determined.
Bacterial clearance rate and measurement of white
blood cells and neutrophilic granulocytes
We evaluated the bacterial clearance rate and investigat-
ed the strains of bacteria. We measured the white
blood cell (WBC) count and neutrophilic granulocyte
percentage (NEU%).
Stable clinical time: The stable clinical time refers to
the time course for the following parameters returning
to a stable condition in moderate or severe CAP pa-
tients: systolic blood pressure ≥90 mm Hg; heart rate ≤
100/min; respiratory rate ≤24/min; body temperature ≤
38°C; and arterial blood oxygen saturation ≥90%.
Quality of life: The World Health Organization quality
of life (WHOQOL)-BREF questionnaire was used to
evaluate the quality of life.
Evaluation of safety: We performed laboratory exami-
nations, including a urine test, electrocardiogram, liver
and renal function, and recorded adverse events and re-
actions.
Statistical analysis
Three patient groups were defined. Patients who went
through randomization and received treatment, and
were observed for at least once were included in the
full-analysis set (FAS) groups. Patients who fully com-
pleted the trial with better compliance were included
in the per-protocol set (PPS) groups. All of the patients
who took the trial medicine at least once were included
in the safety set (SS) groups.
All the P values were two-tailed and the α level of sig-
nificance were set at 0.05. Measurement data are ex-
pressed as mean±standard deviation (mean±SD), medi-
an, or inter-quartile range. The paired-samples t-test or
signed rank sum test was used to compare the differences
between pre-treatment and post-treatment within one
group. The independent-samples t-test was used to com-
pare the differences between the trial group and control
group. Analysis of covariance was used to compare the
differences between centers. Repeated measures were
used to compare the differences of WHOQOL-BREF
score Numerical data are expressed by absolute frequency
or constituent ratio.The chi-square test was used to com-
pare differences between the trial group and control
group. All statistical analyses were undertaken using
SPSS 19.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient enrollment
According to the research protocol, 240 patients were
recruited and underwent randomization. Of these pa-
tients, five patients withdrew (four from the trial group
and one from the control group), and the causes are
shown in Table 1. Therefore, the number of patients in
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the PPS was 235. Of these patients, 116 patients were
in the trial group and 119 were in the control group.
The number of patients in the FAS was 240. There
were no significant differences in demographic and
baseline clinical characteristics between the two groups
(Table 2).
Comparison of therapeutic effects
The total WHOQOL-BREF score in the trial group
was significantly different from that in the control
group (FAS analysis: P=0.003; PPS analysis: P=
0.0007). When adjusting for centers, the WHO-
QOL-BREF score between the two groups was signifi-
cantly different (FAS analysis: P=0.004; PPS analysis:
P<0.0001, Table 3).
Mortality
One patient died in the trial group and two patients
died in the control group. The mortality rate was
0.83% in the trial group and 1.67% in the control
group, with no significant difference between the two
groups (P=1.000).
Bacterial clearance rate
Of the 30 strains of bacteria found in the trial group,
27 disappeared after treatment, and the clearance rate
was 90% . Of the 38 strains of bacteria found in the
control group, 34 disappeared after treatment, and the
clearance rate was 89.47% . Bacterial clearance in the
two groups was not significantly different (P>0.05, Ta-
ble 4).
WBC and NEU%
Both the WBC count and NEU% were investigated
in this study. The WBC count and NEU% were sig-
nificantly decreased after treatment in both of the
groups (P<0.01). After treatment, there was no signif-
icant difference in WBC count between the two
Table 1Withdrawal of patients
Hospital
The First Affiliated Hospital of Henan College of
TCM
Jiangsu Provincial Hospital of TCM
The Affiliate Hospital of Shandong TCM
Qingdao Hospital of TCM
Total No. of the
patients enrolled
52
112
52
24
Withdrawal
Trial group
0
2
0
2
Control group
0
1
0
0
Causes
With Causes Unknown
Consent withdrawn
Age at enrollment (M+Q)
Body-mass index ( xˉ ±s)
Body temperature( xˉ±s)
Ethnicity (n)
Han
Others
Gender (n)
Male
Female
Illness condition (n)
Mild
Moderate
Severe
Subject for full analysis set analysis
Trial group
71±21
23.4±3.1
37.3±1.0
119
1
68
52
31
74
15
Control group
71±18
22.9±2.6
37.5±0.9
119
1
65
55
33
71
16
P value
0.239
0.155
0.223
1.000
0.697
0.897
Trial group
70±21
23.4±3.1
37.3±1.0
115
1
65
51
30
71
15
Subject for per-protocol analysis
Control group
71±18
22.9±2.6
37.5±0.9
118
1
65
54
32
71
16
P value
0.217
0.195
0.159
1.000
0.828
0.938
Table 2 Demographic and baseline clinical characteristics of the patients
Note: TCM: Traditional Chinese Medicine.
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groups (P>0.05). NEU% was not significantly differ-
ent between the two groups by FAS analysis (P>0.05),
but NEU% was significantly different by PPS analysis
(P<0.05, Table 5).
Stable clinical time
Of the total 240 patients, 176 were moderate or severe
patients, and 171 had complete stable clinical time re-
cords. A stable clinical course was achieved in less time
in the trial group compared with that in the control
group (P<0.01, Table 6).
Health-related quality of life
The trial group had a significantly better mean abso-
lute change in the WHOQOL-BREF total score at all
time points compared with the control group (P<
0.001), although the difference in social relationships
was not significant (P>0.05, Table 7).
Evaluation of safety
No serious adverse reactions were found in either of
the two groups during treatment. Progression of dis-
ease caused death in three patients. In the control
group, one patient had occult bleeding (++ ) and one
patient was positive for protein in the urine (+++), but
the results turned to normal when followed up 7 days
later. The other subjects were normal or showed no
clinical significance in routine tests, liver and kidney
function exams, or electrocardiograms. In the trial
group, three patients had mild diarrhea that disap-
peared before the end of treatment, and two had ery-
thra and pruritus, which disappeared with symptomat-
ic treatment. In the control group, three patients had
abdominal discomfort, two had nausea and vomiting,
and one had headache and dizziness. The occurrence of
adverse reactions was 4.17% in the trial group and 5%
in the control group, with no significant difference be-
tween the two groups (P>0.05).
Table 4 Pathogenic bacteria found in the two groups
Pathogenic
bacteria
Streptococcus
mitis
Neisseria
mucosa
Klebiella
pneumonia
Aeruginosus
bacillus
Escherichia
coli
Acinetobacter
baumannii
Acinetobacter
wolfii
Enterobacter
cloacae
Bacillus
diphtheroid
Aeromonas
hydrophila
Candida
albicans
Candida
tropics
Candida
Krusei
Total
Subjects for full analysis set analysis (n)
Trialgroup
(pre-treat.)
9
8
2
2
1
1
0
1
1
1
8
1
0
35
Trial group
(post-treat.)
1
0
0
1
0
0
0
0
0
0
0
1
0
3
Control
group
(pre-treat.)
9
9
2
4
1
1
1
0
0
1
7
1
2
38
Control
group
(post-treat.)
0
0
0
2
0
1
0
0
0
0
1
0
0
4
Subjects for per-protocol analysis (n)
Trial
group
(pre-treat.)
7
6
2
2
1
1
0
1
1
1
7
1
0
30
Trial group
(post-treat.)
1
0
0
1
0
0
0
0
0
0
0
1
0
3
Control
group
(pre- treat.)
9
9
2
4
1
1
1
0
0
1
7
1
2
38
Control
group (post-
treat.)
0
0
0
2
0
1
0
0
0
0
1
0
0
4
Table 3 Comparison of therapeutic effects
Note: aThe comparisons in this category were calculated by using Fisher's exact test. bAccumulation dominance of logistic regression.
Therapeutic
effects
Clinical cure
Marked
improvement
Improvement
Failure
Subjects for full analysis set analysis
Trial
group
[n(%)]
56 (46.7)
46 (38.3)
13(10.8)
5(4.2)
Control
group
[n(%)]
30 (25.0)
71(59.2)
15(12.5)
4(3.3)
P
value
0.003a
Adjusting for
center effect
(P value)
0.004b
Subjects for per-protocol analysis
Trial group
[n(%)]
56(48.3)
46(39.7)
13(11.2)
1(0.9)
Control
group
[n(%)]
29(24.4)
71(59.7)
15(12.6)
4(3.4)
P
value
0.0007a
Adjusting for
center effect
(P value)
0.000b
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Table 5 Results of routine blood tests ( xˉ ±s)
Notes: WBC: white blood cell; NEU%: neutrophilic granulocyte percentage; As compared with pre-treatment, aP<0.01; as compared with
the control group, bP<0.05.
WBC
NEU%
Subjects for full analysis set analysis
Trial group
(pre-treat.)
8.3±4.3
69.8±14.3
Trial group
(post-treat.)
6.5±2.2a
62.8±9.6a
Control
group
(pre-treat.)
9.4±4.6
72.9±12.8
Control
group
(post-treat.)
7.2±6.7
65.3±10.6
Subjects for per-protocol analysis
Trial group
(pre-treat.)
8.4±4.4
69.6±14.5
Trial group
(post-treat.)
6.5±2.2a
62.4±9.4ab
Control
group
(pre-treat.)
9.4±4.6
73.0±12.8
Control
group
(post-treat.)
7.2±6.7
65.3±10.7
Table 7 Health-related quality of life ( xˉ ±s)
Notes: aDifference between the groups;bdifference between the time points;cdifference in interaction between the groups and time points.
Physical
pre-treatment
post-treatment
Follow-up
Psychological
pre-treatment
post-treatment
Follow-up
Environment
pre-treatment
post-treatment
Follow-up
Social relationships
pre-treatment
post-treatment
Follow-up
total score
pre-treatment
post-treatment
Follow-up
Subjects for full analysis set analysis
Trial group
10.1±2.5
12.6±1.6
13.1±1.3
11.1±2.2
13.2±1.9
13.8± 1.8
12.8±2.2
14.4 ±1.7
15.1±1.8
13.2±2.5
14.5±1.8
14.7±2.0
73.9±10.7
83.6±7.4
86.8±7.3
Control
group
9.7±2.6
11.9±1.9
12.0±1.7
10.6 ±2.4
12.6±1.9
12.6±1.8
12.2±2.6
13.6±2.0
13.6±1.7
12.4 ±2.5
14.6±1.7
14.8±1.6
71.6±11.8
79.4±9.5
81.6±9.2
F value
12.607a
220.519b
3.344c
16.747a
222.957b
5.570c
10.320a
112.559b
5.353c
0.872a
109.156b
5.707c
13.038a
293.655b
4.246c
P value
0.008a
0.000b
0.044c
0.000a
0.000b
0.005c
0.002a
0.000b
0.009c
0.351a
0.000b
0.009c
0.000a
0.000b
0.022c
Subjects for per-protocol analysis
Trial group
10.1±2.5
12.6±1.6
13.1±1.4
11.1±2.2
13.3±1.8
14.0±1.7
12.8±2.2
14.4±1.7
15.2±1.8
13.2±2.5
14.5±1.8
14.7±2.0
73.9±10.8
83.7±7.5
86.8±7.4
Control
group
9.7±2.6
11.9±1.9
12.0±1.7
10.6±2.4
12.5±1.9
12.7±1.8
12.2±2.6
13.6±2.0
13.6±1.7
12.5±2.5
14.6±1.7
14.8±1.6
71.5±11.8
79.4±9.5
81.6±9.2
F value
12.758a
215.586b
3.389c
16.701a
217.140b
5.681c
18.052a
157.581b
10.799c
0.775a
103.618b
5.354c
13.126a
284.422b
4.189c
P value
0.000a
0.000b
0.043c
0.000a
0.000b
0.004c
0.000a
0.000b
0.000c
0.380a
0.000b
0.011c
0.000a
0.000b
0.023c
Table 6 Results of the stable clinical time
Trial group
Control group
Z value
P value
Subjects for full analysis set analysis
n
86
85
Clinical stable time
(day, M+Q)
3±1
5±2
-8.677
0.000
Subjects for per-protocol analysis
n
84
85
Clinical stable time
(day, M+Q)
3±1
5±2
-8.682
0.000
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DISCUSSION
CAP is a common illness, and it is the leading cause of
death for elderlypatients.13Clinically,CAPismainly treat-
ed by antimicrobial therapy of Western Medicine,14-16
which improves bacterial clearance, alleviates symp-
toms and signs, and improves pathological changes in
the lung.17 However, with transition of pathogenic mi-
croorganisms and bacterial resistance, the hospitaliza-
tion rate and mortality rate of CAP are rising annually
in aged patients. In recent years, meta-analysis for clini-
cal treatment of CAP has shown that integrated treat-
ment by TCM and Western Medicine is more effective
compared with Western Medicine treatment alone.8 Be-
cause the results of previous studies were limited by
methodological flaws, the high-level evidence is insuffi-
cient. For this reason, in the present study, we per-
formed a randomized controlled multicenter clinical
trial for integrated treatment of CAP based on TCM
syndrome differentiation to evaluate the efficacy and
safety of treatment for CAP, to provide high-level evi-
dence for clinical practice.
The results from the present study showed that inte-
grated treatment based on TCM syndrome differentia-
tion was superior to Western Medicine treatment
alone, with a cure rate of 46.67% in the trial group,
which was nearly twice that of the control group
(25%). However, there was no significant difference in
mortality between the trial group and the control
group. There was also no significant difference in bacte-
rial clearance between the two groups. After treatment,
WBC and NEU% appeared to be decreased in the two
groups compared with pre-treatment, but this differ-
ence was not significant.
Our study showed that patients in the trial group took
less time to achieve a stable clinical course compared
with those in the control group.
In the present study, the trial group showed significant
improvement in all the domains for the mean absolute
change in the WHO QOL-BREF total score, includ-
ing physical and psychological health, social relation-
ships, and environment.
Our study shows that among patients with CAP who
receive western medications, the addition of TCM
once daily for 14 days does not result in changes in
mortality. However, advantages of TCM treatment in-
clude less time to achieve a stable clinical condition,
improvement of clinical symptoms and quality of life,
and it is comparatively safe.
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